| Overview |
| bs-11677R-Cy5 |
| UCHL1+3 Polyclonal Antibody, Cy5 Conjugated |
| WB, IF(IHC-P), IF(IHC-F), IF(ICC) |
| Human, Mouse |
| Rat, Dog, Sheep, Pig, Horse, Rabbit |
| Specifications |
| Cy5 |
| Rabbit |
| KLH conjugated synthetic peptide derived from human UCHL1+3 |
| 141-223/223 |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| Cytoplasm, Cell membrane |
| Ubiquitin C terminal esterase L1; Ubiquitin carboxyl terminal esterase L1; Ubiquitin carboxyl terminal esterase L3; Ubiquitin carboxyl terminal hydrolase isozyme L1; Ubiquitin carboxyl terminal hydrolase isozyme L3; Ubiquitin thiolesterase; UCHL1; UCHL3. |
| The two ubiquitin C-terminal hydrolase (UCH) enzymes, UCHL1 and UCHL3, deubiquitinate ubiquitin-protein conjugates and control the cellular balance of ubiquitin. UCHL1 and UCHL3 are both small proteins of ~220 amino acids that share more than 40% amino acid sequence identity. UCHL3 is universally expressed in all tissues, while UCHL1 is expressed exclusively in neuronal tissue, testis and ovary. The activity of UCHL3 is more than 200 fold higher than UCHL1 when a fluorogenic ubiquitin substrate is used. UCHL1 associates with monoubiquitin and UCHL3 binds to Nedd8, ubiquitin-like protein. UCHL1 and UCHL3 play a role in the regulation of neuronal development and spermatogenesis. UCHL1 is involved in the pathogenesis of Parkinson?s disease (PD) and Alzheimer?s disease (AD). |
| Application Dilution |
| WB |
1:300-5000 |
| IF(IHC-P) |
1:50-200 |
| IF(IHC-F) |
1:50-200 |
| IF(ICC) |
1:50-200 |
Powered by Bioz